No Data
No Data
Outlook Therapeutics Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
Buy Rating Affirmed for Outlook Therapeutics Amid Strong Market Potential and Upcoming Milestones for ONS-5010/Lytenava
Express News | Outlook Therapeutics: Topline Results From Norse Eight Expected in Q4 Cy2024
Express News | Outlook Therapeutics Inc - Ons-5010 Bla Resubmission Planned for Q1 Cy2025
Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
Express News | Outlook Therapeutics® Announces Completion of Enrollment in Norse Eight Clinical Trial